Literature DB >> 17101675

Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.

Hongmei Mo1, Neil Parkin, Kent D Stewart, Liangjun Lu, Tatyana Dekhtyar, Dale J Kempf, Akhteruzzaman Molla.   

Abstract

Two novel human immunodeficiency virus protease mutations, I84C and I84A, were identified in patient isolates. The mutants with I84C displayed high-level resistance (median, at least 56-fold) to nelfinavir and saquinavir, but the majority remained susceptible to lopinavir. In contrast, isolates with the I84A mutation exhibited>or=33-fold median increased levels of resistance to nelfinavir, indinavir, amprenavir, ritonavir, lopinavir, saquinavir, and atazanavir. Isolates with the I84A or I84C mutation tended to be more resistant than the isolates with the I84V mutation. Modeling of the structure of the mutant proteases indicated that the I84V, I84C, and I84A mutations all create unoccupied volume in the active site, with I84A introducing the greatest change in the accessible surface area from that of the wild-type structure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101675      PMCID: PMC1797770          DOI: 10.1128/AAC.00690-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Structural parameterization of the binding enthalpy of small ligands.

Authors:  Irene Luque; Ernesto Freire
Journal:  Proteins       Date:  2002-11-01

3.  Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.

Authors:  Louise Doyon; Sonia Tremblay; Lise Bourgon; Elizabeth Wardrop; Michael G Cordingley
Journal:  Antiviral Res       Date:  2005-10       Impact factor: 5.970

4.  Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.

Authors:  Fengling Liu; Peter I Boross; Yuan-Fang Wang; Jozsef Tozser; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2005-10-21       Impact factor: 5.469

5.  Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.

Authors:  D J Kempf; J D Isaacson; M S King; S C Brun; Y Xu; K Real; B M Bernstein; A J Japour; E Sun; R A Rode
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Authors:  C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.

Authors:  Nicola Gianotti; Elena Seminari; Monica Guffanti; Enzo Boeri; Paola Villani; Mario Regazzi; Alba Bigoloni; Giulia Schira; Simon Tiberi; Giuliana Fusetti; Adriano Lazzarin; Antonella Castagna
Journal:  New Microbiol       Date:  2005-04       Impact factor: 2.479

Review 8.  Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.

Authors:  Cédric Arvieux; Olivier Tribut
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.

Authors:  Richard Colonno; Ronald Rose; Colin McLaren; Alexandra Thiry; Neil Parkin; Jacques Friborg
Journal:  J Infect Dis       Date:  2004-04-27       Impact factor: 5.226

10.  Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma.

Authors:  Thomas B Campbell; Kristina Schneider; Terri Wrin; Christos J Petropoulos; Elizabeth Connick
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more
  9 in total

1.  HIV-1 protease mutations and protease inhibitor cross-resistance.

Authors:  Soo-Yon Rhee; Jonathan Taylor; W Jeffrey Fessel; David Kaufman; William Towner; Paolo Troia; Peter Ruane; James Hellinger; Vivian Shirvani; Andrew Zolopa; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

2.  Pulsed EPR characterization of HIV-1 protease conformational sampling and inhibitor-induced population shifts.

Authors:  Zhanglong Liu; Thomas M Casey; Mandy E Blackburn; Xi Huang; Linh Pham; Ian Mitchelle S de Vera; Jeffrey D Carter; Jamie L Kear-Scott; Angelo M Veloro; Luis Galiano; Gail E Fanucci
Journal:  Phys Chem Chem Phys       Date:  2016-02-17       Impact factor: 3.676

Review 3.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

4.  The role of select subtype polymorphisms on HIV-1 protease conformational sampling and dynamics.

Authors:  Xi Huang; Manuel D Britto; Jamie L Kear-Scott; Christopher D Boone; James R Rocca; Carlos Simmerling; Robert Mckenna; Michael Bieri; Paul R Gooley; Ben M Dunn; Gail E Fanucci
Journal:  J Biol Chem       Date:  2014-04-17       Impact factor: 5.157

5.  Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.

Authors:  Shanmugam Saravanan; Madhavan Vidya; Pachamuthu Balakrishnan; Rami Kantor; Sunil S Solomon; David Katzenstein; Nagalingeswaran Kumarasamy; Tokugha Yeptomi; Sathasivam Sivamalar; Samara Rifkin; Kenneth H Mayer; Suniti Solomon
Journal:  Clin Infect Dis       Date:  2012-02-09       Impact factor: 9.079

6.  Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.

Authors:  Sidonie Lambert-Niclot; Philippe Flandre; Ana Canestri; Gilles Peytavin; Christine Blanc; Rachid Agher; Cathia Soulié; Marc Wirden; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

7.  Elucidating a relationship between conformational sampling and drug resistance in HIV-1 protease.

Authors:  Ian Mitchelle S de Vera; Adam N Smith; Maria Cristina A Dancel; Xi Huang; Ben M Dunn; Gail E Fanucci
Journal:  Biochemistry       Date:  2013-05-01       Impact factor: 3.162

8.  HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes.

Authors:  Guangdi Li; Jens Verheyen; Kristof Theys; Supinya Piampongsant; Kristel Van Laethem; Anne-Mieke Vandamme
Journal:  Retrovirology       Date:  2014-09-25       Impact factor: 4.602

Review 9.  Human Immunodeficiency Virus Gag and protease: partners in resistance.

Authors:  Axel Fun; Annemarie M J Wensing; Jens Verheyen; Monique Nijhuis
Journal:  Retrovirology       Date:  2012-08-06       Impact factor: 4.602

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.